Connection

P Rajagopalan to Antigens, CD

Back to Details
This is a "connection" page, showing publications P Rajagopalan has written about Antigens, CD.
P Rajagopalan
Connection Strength
0.016
Antigens, CD
  1. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007 Jul; 7(7):1770-7.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.